enGene Therapeutics Inc. (ENGNW)
| Market Cap | 107.18M -43.8% |
| Revenue (ttm) | n/a |
| Net Income | -122.44M |
| EPS | -2.22 |
| Shares Out | 66.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Open | 0.2002 |
| Previous Close | 0.2500 |
| Day's Range | 0.2000 - 0.2002 |
| 52-Week Range | 0.1113 - 4.2000 |
| Beta | -0.29 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 12, 2026 |
About ENGNW
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based... [Read more]
News
enGene Therapeutics Transcript: AGM 2026
The meeting confirmed quorum, reviewed and approved the election of four directors until 2029, and reappointed KPMG LLP as auditor. All proposals passed with strong shareholder support, and no questions were raised on the main items.
enGene price target lowered to $2 from $9 at UBS
UBS lowered the firm’s price target on enGene (ENGN) to $2 from $9 and keeps a Neutral rating on the shares.
Leerink downgraded enGene to Market Perform following LEGEND update
As previously reported, Leerink downgraded enGene (ENGN) to Market Perform from Outperform with a price target of $2, down from $19, following the “disappointing” LEGEND update as key debates around…
enGene downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded enGene (ENGN) to Perform from Outperform. The firm views updated interim data from the pivotal LEGEND cohort in BCG-unresponsive NMIBC as disappointing, and while the approval d...
enGene downgraded to Market Perform from Outperform at Leerink
Leerink downgraded enGene (ENGN) to Market Perform from Outperform with a $2 price target
enGene Therapeutics Proxy statement: Proxy filing
enGene Therapeutics filed a proxy statement on May 8, 2026, providing details for shareholder voting and corporate governance matters.
enGene downgraded to Outperform from Strong Buy at Raymond James
Raymond James downgraded enGene (ENGN) to Outperform from Strong Buy with a price target of $4, down from $27, after the company announced interim results from the pivotal cohort of…
enGene downgraded to Neutral from Buy at Guggenheim
Guggenheim yesterday downgraded enGene (ENGN) to Neutral from Buy without a price target after the company announced interim results from the pivotal cohort of LEGEND, evaluating detalimogene in BCG-u...
enGene downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler analyst Allison Bratzel downgraded enGene (ENGN) to Neutral from Overweight with a price target of $4, down from $7, after the company announced interim results from the pivotal…
enGene downgraded to Market Perform from Outperform at Citizens
Citizens downgraded enGene (ENGN) to Market Perform from Outperform without a price target The company’s updated results from the pivotal LEGEND study “worsened significantly,” the analyst tells inves...
enGene downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo downgraded enGene (ENGN) to Equal Weight from Overweight with a price target of $2, down from $25. The company’s efficacy data for detalimogene is weaker than the last…
enGene downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Judah Frommer downgraded enGene (ENGN) to Equal Weight from Overweight without a price target after the company announced interim results from the pivotal cohort of LEGEND, eval...
enGene downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded enGene (ENGN) to Neutral from Buy.
enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ: ENGN). The investigation focuses on enGen...
enGene announces updated interim results from LEGEND cohort
enGene (ENGN) Therapeutics reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid in high-risk, Bacillus Calmette-Guerin-unrespons...
enGene Therapeutics Transcript: Study result
LEGEND pivotal cohort data show detalimogene achieves a 54% CR at any time and 43% at six months, with strong tolerability and low discontinuation rates. Lower CR rates in the latest subgroup are under review, and a new surfactant cohort aims to boost efficacy. BLA filing is planned after full data maturation.
enGene Therapeutics Slides: Study result
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
enGene Therapeutics Press release: Study result
enGene Therapeutics issued a press release on May 7, 2026, disclosing material business information to investors.
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional interim resul...
enGene initiated with a Buy at WBB Securities
WBB Securities initiated coverage of enGene (ENGN) with a Buy rating and $21.50 price target
enGene Therapeutics Slides: Corporate presentation
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 10, 2026.
enGene announces name change to enGene Therapeutics
enGene (ENGN) will change its corporate name to “enGene Therapeutics Inc.” effective April 8. The Company elected to change its corporate name to reflect the near-term transition to a commercial…
enGene Announces Name Change to enGene Therapeutics Inc.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleas...
enGene price target lowered to $9 from $10 at UBS
UBS analyst David Dai lowered the firm’s price target on enGene (ENGN) to $9 from $10 and keeps a Neutral rating on the shares following the fiscal Q1 report. The…
enGene Therapeutics Transcript: The Citizens Life Sciences Conference 2026
NMIBC treatment is shifting from radical surgery to more tolerable, effective therapies, with detalimogene showing strong efficacy and ease of use for community urologists. Key data updates are expected in Q2 and later this year, supporting a potential 2027 approval.